

## Part VI: Summary of the Risk Management Plan

As the safety concerns and their management are identical for all products covered by this RMP, the information in Part VI is presented only once together for all products.

### Summary of risk management plan for Macitentan Zentiva/Macitentan Zentiva k.s. (macitentan)

This is a summary of the risk management plan (RMP) for Macitentan Zentiva/Macitentan Zentiva k.s.. The RMP details important risks of Macitentan Zentiva/Macitentan Zentiva k.s., how these risks can be minimised, and how more information will be obtained about Macitentan Zentiva/Macitentan Zentiva k.s.'s risks and uncertainties (missing information).

Macitentan Zentiva/Macitentan Zentiva k.s.'s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Macitentan Zentiva/Macitentan Zentiva k.s. should be used.

Important new concerns or changes to the current ones will be included in updates of Macitentan Zentiva/Macitentan Zentiva k.s.'s RMP.

#### *I. The medicine and what it is used for*

Macitentan Zentiva/Macitentan Zentiva k.s., is authorised for the long-term treatment of pulmonary arterial hypertension in adult and paediatric (bodyweight  $\geq 40$  kg) patients of WHO Functional Class (FC) II to III (see SmPC for the full indication). It contains macitentan as the active substance and it is given by oral route of administration.

#### *II. Risks associated with the medicine and activities to minimise or further characterise the risks*

Important risks of Macitentan Zentiva/Macitentan Zentiva k.s., together with measures to minimise such risks and the proposed studies for learning more about Macitentan Zentiva/Macitentan Zentiva k.s.'s risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In the case of Macitentan Zentiva/Macitentan Zentiva k.s., these measures are supplemented with additional risk minimisation measures mentioned under relevant important risks, below.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Macitentan Zentiva/Macitentan Zentiva k.s. is not yet available, it is listed under 'missing information' below.

## II.A List of important risks and missing information

Important risks of Macitentan Zentiva/Macitentan Zentiva k.s. are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Macitentan Zentiva/Macitentan Zentiva k.s.. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	<ul style="list-style-type: none"> <li>• Hepatotoxicity</li> <li>• Teratogenicity</li> </ul>
Important potential risks	<ul style="list-style-type: none"> <li>• None</li> </ul>
Missing information	<ul style="list-style-type: none"> <li>• None</li> </ul>

## II.B Summary of important risks

Summary of important risk that have corresponding additional risk minimisation activities are:

Important identified risk: Hepatotoxicity	
Risk minimisation measures	<u>Routine risk minimisation measures:</u> SmPC section 4.3, 4.4 and 4.8 PL section 2 and 4 Medicinal product subject to restricted medical prescription.  <u>Additional risk minimisation measures:</u> <b>Educational tools (patient card)</b>

Important identified risk: Teratogenicity	
Risk minimisation measures	<u>Routine risk minimisation measures:</u> SmPC section 4.3, 4.4 and 4.6 PL section 2 Medicinal product subject to restricted medical prescription.  <u>Additional risk minimisation measures:</u> <b>Educational tools (patient card)</b>

## II.C Post-authorisation development plan

### II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Macitentan Zentiva/Macitentan Zentiva k.s..

### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for Macitentan Zentiva/Macitentan Zentiva k.s..